Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L6 pseudogene 24 (RPL6P24) is a processed pseudogene, meaning it is a non-functional DNA segment derived from the functional ribosomal protein L6 gene (RPL6)[2][4]. Pseudogenes like RPL6P24 are common in the human genome; they arise via sequence homology and retrotransposition, resulting in copies that lack regulatory elements or contain disabling mutations, preventing functional protein expression[4]. The parent gene, RPL6, encodes a structural component of the large 60S ribosomal subunit, essential for protein synthesis[5][7]. However, as a pseudogene, RPL6P24 does not encode a functional protein, has no known direct biological function, and is not considered a therapeutic target[4][5][7]. There are about 30 processed pseudogenes for RPL6 in humans, none known to be functional or druggable[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L6 pseudogene 24 (RPL6P24).